Abstracts tagged "proteomics and salivary hypofunction"

Abstract Number: 556 • 2017 ACR/ARHP Annual Meeting
Identification and Validation of S100 Salivary Proteins As Putative Biomarkers for Different Subsets of Primary Sjögren’s Syndrome Patients
Chiara Baldini¹, Francesco Ferro², Nadia Ucciferri³, Enza Polizzi², Silvia Rocchiccioli³, Marta Mosca² and Antonella Cecchettini³, ¹Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³IFC, CNR, Pisa, Italy
Background/Purpose: S100 A proteins are multifunctional proteins expressed predominantly by myeloid cells, with a regulatory role in a variety of cellular processes including inflammation. Recently,…
Abstract Number: 2797 • 2015 ACR/ARHP Annual Meeting
Identification of Serum Biomarker for the Glandular Dysfunction of Primary Sjögren’s Syndrome
Ayumi Nishikawa¹, Katsuya Suzuki¹, Yoshiaki Kassai², Yuumi Gotou³, Takahiro Miyazaki⁴, Maiko Takiguchi⁴, Rimpei Morita⁵, Akihiko Yoshimura⁵ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Takeda Pharmaceutical Company, Fujisawa, Japan, ³Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, ⁴Inflammation Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Ltd., Kanagawa, Japan, ⁵Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by dry eye and mouth. Measurements of un-stimulated salivary flow and Schirmer’s test are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].